CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 - CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results a...
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study () of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (Ep...
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB col...
Liquidity Services Announces Second Quarter Fiscal Year 2024 Earnings Conference Call BETHESDA, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ:LQDT), a leading global commerce company powering the circular economy, today announced that it expects to report its second quarter fiscal year 2024 results prior to market open on Thursday, May 9, 2024. Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will then host a conference call to review the results at 10:30 AM Eastern Time. To participate in the conference call, please to receive the dial-in number and u...
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors. “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “With his extensive experience and accomplis...
Homology Medicines Declares Distribution to Common Stockholders BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024...
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX...
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PD...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.